Table 3.

Patient preferences for treatment attributes (overall population^a)

Treatment attributes	Estimate	95% CI	p value
Efficacy
Cure rate (per  % change)	0.311	(0.267, 0.356)	< 0.001*
Convenience
Treatment duration (per week)
8 weeks vs. 12 weeks	0.255	(0.090, 0.419)	0.002*
16 weeks vs. 12 weeks	− 0.061	(− 0.219, 0.097)	0.447
24 weeks vs. 12 weeks	− 0.321	(− 0.505, − 0.138)	< 0.001*
Once-daily tablet count and packaging
1 tablet from a prescription bottle vs. 1 tablet in a single-dose blister pack	0.090	(− 0.035, 0.216)	0.159
3 tablets in a single-dose blister pack vs. 1 tablet in a single-dose blister pack	− 0.034	(− 0.171, 0.103)	0.624
Visits during HCV treatments
Simplified monitoring (no in-person visit, e.g., telephone checking in) vs. two additional office visits	0.131	(− 0.036, 0.298)	0.124
One additional office visit vs. two additional office visits	0.170	(0.005, 0.336)	0.044*
Co-therapy management
Modification of statins
Temporarily reduce dose or stop taking vs. no modification	− 0.105	(− 0.249, 0.039)	0.152
Switch to a different medication vs. no modification	− 0.129	(− 0.296, 0.038)	0.131
Modification of PPIs
Temporarily reduce dose/timing or stop taking vs. no modification	− 0.171	(− 0.326, − 0.015)	0.032*
Switch to a different medication vs. no modification	− 0.125	(− 0.298, 0.047)	0.155
Mild common side effects
Risk of adverse events (per % change)
Diarrhea	− 0.033	(− 0.040, − 0.025)	< 0.001*
Headache	− 0.028	(− 0.034, − 0.022)	< 0.001*
Nausea	− 0.028	(− 0.036, − 0.019)	< 0.001*

^aAll patients from the USA and the five European countries (UK, France, Germany, Spain, and Italy)

*p value < 0.05